We read with interest the recent article by Takeda et al. ([@B1]) suggesting a beneficial role of ACE type 2 (ACE2) in type 2 diabetes. We would like to share our recent observations ([@B2]) complementing this work. Takeda et al. showed that lack of ACE2 did not affect baseline glycemia, as reported previously ([@B3]), but promoted impaired glucose tolerance and insulin resistance when the mice were fed a hypercaloric diet. Surprisingly, this diet failed to increase fasting glucose, triglycerides, and blood pressure levels in all groups. Interestingly, the authors showed that when infused with angiotensin II (Ang-II) (100 ng/kg/min), only ACE2 knockout mice exhibited impaired glucose tolerance and insulin resistance. Similarly, we observed that a higher dose of Ang-II (200 ng/kg/min) led to the same results in C57Bl/6 wild-type mice and was associated with downregulation of ACE2 and upregulation of Ang-II type 1 receptors in the pancreas ([@B2]).

Takeda et al. ([@B1]) elegantly showed that the ACE2/angiotensin 1--7/Mas receptor signaling pathway is required to maintain normal insulin sensitivity in the presence of high Ang-II levels in liver and soleus muscle, extending our previous observations that ACE2 knockout mice have impaired levels of Mas receptors in the pancreas ([@B4]). Further, supporting the role of this compensatory axis, we previously reported that Mas receptor blockade prevented the beneficial effects of ACE2 gene therapy in reducing hyperglycemia in *db/db* mice ([@B5]). Moreover, we showed the benefits of maintaining physiological levels of ACE2 in the pancreas and the islets of Langerhans in order to counteract hyperglycemia in Ang-II--infused mice ([@B2]).

To unfold the mechanisms involved, Takeda et al. ([@B1]) demonstrated that regulation of myocyte enhancer factor 2A and GLUT4 expression by the ACE2/angiotensin 1--7/Mas receptor axis contribute to the improvement of insulin sensitivity. Adding to these, we observed that ACE2 improves β-cell function by counteracting Ang-II--mediated oxidative stress in the pancreas ([@B2]).

Altogether, the recent reports by Takeda et al. ([@B1]) and our group ([@B2]) support and extend previous observations ([@B3]--[@B5]) suggesting the therapeutic potential of ACE2 to control type 2 diabetes. Hence, strategies to restore ACE2 activity in diabetes need to be further investigated in order to utilize the beneficial effects of ACE2 in the regulation of glycemia.
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